SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
For more information, view the ICARIA-MM phase 3 trial design.
SARCLISA is indicated, in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
For more information, view the IKEMA phase 3 trial results.